Drugs /

aldesleukin

Back to Drugs List
Associated Genetic Biomarkers

Overview

Trade Name(s):
Proleukin
NCI Definition [1]:
A recombinant analog of the endogenous cytokine interleukin-2 (IL-2) with immunoregulatory and antineoplastic activities. Aldesleukin binds to and activates the IL-2 receptor, followed by heterodimerization of the cytoplasmic domains of the IL-2R beta and gamma(c) chains; activation of the tyrosine kinase Jak3; and phosphorylation of tyrosine residues on the IL-2R beta chain, resulting in an activated receptor complex. Various cytoplasmic signaling molecules are recruited to the activated receptor complex and become substrates for regulatory enzymes that are associated with the receptor complex. This agent enhances lymphocyte mitogenesis; stimulates long-term growth of human IL-2 dependent cell lines; enhances lymphocyte cytotoxicity; induces lymphokine-activated killer (LAK) cell and natural killer (NK) cell activities; and induces expression of interferon-gamma. Aldesleukin may induce T cell-mediated tumor regression in some tumor types.

Clinical Trials

View Clinical Trials for aldesleukin

Aldesleukin has been investigated in 58 clinical trials, of which 40 are open and 18 are closed. Of the trials investigating aldesleukin, 2 are early phase 1 (2 open), 18 are phase 1 (15 open), 17 are phase 1/phase 2 (10 open), 19 are phase 2 (11 open), and 2 are phase 3 (2 open).

HLA-A*02:01 Positive, CTAG1A Expression, and CTAG1B Expression are the most frequent biomarker inclusion criteria for aldesleukin clinical trials.

Melanoma, malignant solid tumor, and neuroblastoma are the most common diseases being investigated in aldesleukin clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Aldesleukin
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Aldesleukin
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating aldesleukin and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
interleukin-2, 125-l-serine-2-133-interleukin 2, recombinant interleukin-2, interleukin-2(2-133),125-ser, thymocyte stimulating factor, interleukin ii, Proleukin, r-serhuil-2, tcgf, interleukin, recombinant human interleukin-2, lymphocyte mitogenic factor, tsf, 2-133-interleukin 2 (human reduced), 125-l-serine-, aldesleukin (substance), il-2, 125-l-serine-2-133-interleukin 2, 125-l-serine-2-133-interleukin 2 (human reduced), 110942-02-4, recombinant interleukin-2 human, aldesleukin, aldesleukin (product), recombinant human interleukin-2, aldesleukin [chemical/ingredient], t-cell growth factor, mitogenic factor, interleukin 2, recombinant human il-2, tcgf, aldesleukin product, interleukin-2 aldesleukin
Drug Categories [2]:
Immunotherapies
Drug Target(s) [2]:
IL2RA, IL2RB, IL2RG
NCIT ID [1]:
C1498
SNOMED ID [1]:
F-61B2B

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.